Search
Hexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Aminomethylbenzoic acid
go.drugbank.com/drugs/DB13244ExperimentalAminomethylbenzoic acid may be useful as an antifibrinolytic agent [A174994].
Canakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalwell as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). … for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as
NUC B1000
go.drugbank.com/drugs/DB05242ExperimentalOn January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection.
CRx-139
go.drugbank.com/drugs/DB05744ExperimentalCRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dos...
Marimastat
go.drugbank.com/drugs/DB00786InvestigationalAs an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
Furvina
go.drugbank.com/drugs/DB16547ExperimentalFurvina is marketed in Cuba as Dermofural®, an ointment containing G1 as the only active principle ingredient. It is used to treat dermatological infections.[A228063]
Cathine
go.drugbank.com/drugs/DB01486ExperimentalIllicitIn the United States, it is classified as a Schedule IV controlled substance. … Cathine, also known as d-norpseudoephedrine and (+)-norpseudoephedrine, is a psychoactive drug with stimulant properties. It belongs to the phenethylamine and amphetamine chemical classes.
SNX-5422
go.drugbank.com/drugs/DB06070InvestigationalAs an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.